AI for Pharma & Healthcare 2025

NeoGenomics to acquire GE Cancer Testing Unit Clarient

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Philips, Masimo Extend Partnership to Sensor...

Philips and Masimo have gone on to renew their...

Renovo from China Raises $67M Series...

Ronovo Surgical from China has gone on to close...

NHS Boards to Explore Joint Working...

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients...

The NHS in England has remained under relentless pressure...
NeoGenomics Inc. agreed to acquire Clarient Inc., a subsidiary of the health-care unit of General Electric Co. , in a deal potentially valued at $275.2 million that aims to broaden the genetic-testing company’s offerings of cancer diagnostic tests.
Under the deal, NeoGenomics will acquire the cancer diagnostic testing firm for $80 million in cash, $110 million in preferred stock, and 15 million shares of NeoGenomics common stock—valued at roughly at $85.2 million based on Tuesday’s closing price.
NeoGenomics Chairman and Chief Executive Douglas VanOort said NeoGenomics and GE Healthcare have agreed to collaborate on a new bioinformatics initiative that will explore the potential for new products that combine genomic and imaging data.
Clarient had revenue of $127 million last year and has roughly 415 employees.
NeoGenomics said that Clarient’s capabilities in testing for solid tumor cancers of the breast, colon and lung are highly complementary to its capabilities in testing hematologic cancers.
The company expects cost savings of $4 million to $6 million next year, with annual cost savings rising to $20 million to $30 million by the end of the third year following the deal.

Latest stories

Related stories

Philips, Masimo Extend Partnership to Sensor Technologies

Philips and Masimo have gone on to renew their...

Renovo from China Raises $67M Series D Funding by JJDC

Ronovo Surgical from China has gone on to close...

NHS Boards to Explore Joint Working in Sussex and Surrey

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients Volume Grows

The NHS in England has remained under relentless pressure...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »